🇺🇸 FDA
Patent

US 9365848

Modulation of apolipoprotein C-III expression

granted A61KA61K38/00A61P

Quick answer

US patent 9365848 (Modulation of apolipoprotein C-III expression) held by Ionis Pharmaceuticals, Inc. expires Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Ionis Pharmaceuticals, Inc.
Grant date
Tue Jun 14 2016 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 09 2036 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
16
CPC classes
A61K, A61K38/00, A61P, A61P3/00, A61P3/04